Status:
COMPLETED
A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.
Lead Sponsor:
Pfizer
Conditions:
Breast Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Assessment of safety and efficacy of SU11248 in patients with metastatic breast cancer who have failed selected other therapies.
Eligibility Criteria
Inclusion
- Anthracycline and taxane-refractory or intolerant metastatic breast cancer
- Female
Exclusion
- Prior treatment with 3 or greater regimens of chemotherapy in the advanced/metastatic disease setting beyond those containing anthracyclines/taxanes.
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2005
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00078000
Start Date
March 1 2004
End Date
November 1 2005
Last Update
November 26 2008
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Greenbrae, California, United States, 94904
2
Pfizer Investigational Site
Los Angeles, California, United States, 90095
3
Pfizer Investigational Site
San Francisco, California, United States, 94115
4
Pfizer Investigational Site
Aurora, Colorado, United States, 80010